Skip to main content
CSPC Pharmaceutical Group Limited logo

CSPC Pharmaceutical Group Limited — Investor Relations & Filings

Ticker · 1093 ISIN · US12591J1088 LEI · 529900M3XQCW234H8O91 HKEX Manufacturing
Open in API
Filings indexed 1,520 across all filing types
Latest filing 2023-06-12 Regulatory Filings
Country HK Hong Kong
Listing HKEX 1093

About CSPC Pharmaceutical Group Limited

https://www.cspc.com.hk/en/global/home.…

CSPC Pharmaceutical Group Limited is a comprehensive enterprise specializing in the research, development, manufacturing, and sale of pharmaceutical products. The company operates across two main segments: finished drugs and bulk drugs. It emphasizes innovation and new drug development, evidenced by substantial R&D investment, to produce high-quality, effective, and reliable medicines. Its portfolio includes key innovative products such as NBP (soft capsules and injections), Oulaining, and Enxi, which are among its top-selling drugs.

Recent filings

Filing Released Lang Actions
VOLUNTARY ANNOUNCEMENT - SELECTIVE ATM INHIBITOR SYH2051 OBTAINS CLINICAL TRIAL APPROVAL
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by the board of directors of CSPC Pharmaceutical Group Limited regarding the clinical trial approval of a new drug product (SYH2051). It is not a financial report, earnings release, or regulatory filing related to financial performance. The document is short (2194 characters) and serves as an announcement of a significant event related to the company's product development. There is no indication of financial data, management discussion, or regulatory compliance filings. It is not related to board or management changes, voting results, or capital structure updates. Therefore, the best fitting category is Regulatory Filings (RNS), which serves as a fallback for miscellaneous announcements that do not fit other specific categories.
2023-06-12 English
VOLUNTARY ANNOUNCEMENT - CPO301 WAS GRANTED FAST TRACK DESIGNATION BY THE U.S. FDA
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by the board of directors of CSPC Pharmaceutical Group Limited regarding the FDA granting Fast Track Designation to their drug CPO301. It contains no financial data, no detailed financial statements, no regulatory certifications, or voting results. The document is relatively short (3562 characters) and serves as a news update about a clinical development milestone rather than a formal financial or regulatory filing. It does not fit into categories like Annual Report, Earnings Release, or Regulatory Filings. It is an announcement about a significant corporate development related to product development and regulatory status. Given the content and nature, the best fitting category is Regulatory Filings (RNS), which is the fallback for miscellaneous announcements that do not fit other categories.
2023-06-12 English
VOLUNTARY ANNOUNCEMENT - CPO301 OBTAINS CLINICAL TRIAL APPROVAL IN CANADA
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by the board of directors of CSPC Pharmaceutical Group Limited regarding the approval of a clinical trial application in Canada. It is a short announcement (2166 characters) and does not contain financial data, detailed financial performance, or regulatory certifications. It is not a full report like an Annual Report (10-K) or Interim Report (IR), nor is it a call transcript or management report. The content focuses on a clinical trial approval, which is a corporate update but not related to capital/financing, board changes, or legal proceedings. Given the short length and nature as an announcement, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2023-06-08 English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 MAY 2023
Regulatory Filings Classification · 95% confidence The document is titled 'Monthly Return for Equity Issuer and Hong Kong Depositary Receipts listed under Chapter 19B of the Exchange Listing Rules on Movements in Securities' for the month ended 31 May 2023. It details movements in issued shares, share options, and confirms no changes in authorized share capital or other share-related movements. The document is a regulatory submission to the Hong Kong Exchanges and Clearing Limited, reporting share capital and share option movements for a specific month. It is not a financial report, earnings release, or management discussion. It is a regulatory filing related to share capital movements and compliance with listing rules. The document length is about 5,096 characters, and it is a formal regulatory return rather than a report or announcement of a report. Therefore, the best fitting category is Regulatory Filings (RNS).
2023-06-02 English
POLL RESULTS OF ANNUAL GENERAL MEETING HELD ON 31 MAY 2023
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is an announcement of the poll results from the Annual General Meeting (AGM) held on 31 May 2023. It details the voting outcomes on various resolutions including receiving the audited financial statements, dividend declaration, re-election of directors, appointment of auditors, and mandates for share buy-back and issuance. The document does not contain the full annual report or financial statements themselves but reports the voting results on these matters. It explicitly states it is the poll results of the AGM. Therefore, this document fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length (5567 characters) and content confirm it is not merely a brief notice but a detailed voting result announcement. Confidence is high due to clear keywords such as 'poll results', 'AGM', and detailed voting percentages for resolutions.
2023-05-31 English
VOLUNTARY ANNOUNCEMENT - CLINICAL DATA OF ALMB-0168 FOR THE TREATMENT OF OSTEOSARCOMA TO BE PRESENTED AT THE 2023 ASCO ANNUAL MEETING
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by the board of directors of CSPC Pharmaceutical Group Limited regarding the presentation of clinical data for a drug candidate (ALMB-0168) at an upcoming medical conference (2023 ASCO Annual Meeting). It contains no financial data, no regulatory filings, no voting results, no management changes, no earnings or financial reports, and no capital or share-related information. The content focuses on clinical trial results and their presentation, which is typical of a voluntary announcement to inform the market about scientific progress rather than a formal financial or regulatory filing. The document is relatively short (3608 characters) and is an announcement rather than a report or transcript. Therefore, it best fits the category of Regulatory Filings (RNS) as a general announcement that does not fit other specific categories.
2023-05-30 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.